413 related articles for article (PubMed ID: 17413573)
1. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
2. Frequency of Thyroid Microcarcinoma in Patients Who Underwent Total Thyroidectomy with Benign Indication-A 5-Year Retrospective Review.
Magra V; Boulogeorgou K; Paschou E; Sevva C; Manaki V; Mpotani I; Mantalovas S; Laskou S; Kesisoglou I; Koletsa T; Sapalidis K
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541194
[No Abstract] [Full Text] [Related]
3. Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer.
van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
J Clin Endocrinol Metab; 2020 Mar; 105(3):e457-65. PubMed ID: 31665318
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.
Sabra MM; Dominguez JM; Grewal RK; Larson SM; Ghossein RA; Tuttle RM; Fagin JA
J Clin Endocrinol Metab; 2013 May; 98(5):E829-36. PubMed ID: 23533233
[TBL] [Abstract][Full Text] [Related]
5. Initial treatment patterns in younger adult patients with differentiated thyroid cancer in California.
Semrad TJ; Semrad AM; Farwell DG; Chen Y; Cress R
Thyroid; 2015 May; 25(5):509-13. PubMed ID: 25744759
[TBL] [Abstract][Full Text] [Related]
6. Thyroid cancer presentation and treatment in the United States.
Enewold L; Harlan LC; Stevens JL; Sharon E
Ann Surg Oncol; 2015; 22(6):1789-97. PubMed ID: 25361888
[TBL] [Abstract][Full Text] [Related]
7. Impact of radioiodine therapy on recurrence and survival outcomes in intermediate-risk papillary thyroid carcinoma -A systematic review and meta-analysis.
Chandekar KR; Satapathy S; Bal C
Clin Endocrinol (Oxf); 2024 Feb; 100(2):181-191. PubMed ID: 38050454
[TBL] [Abstract][Full Text] [Related]
8. An upper cervical cord compression secondary to occult follicular thyroid carcinoma metastases successfully treated with multiple radioiodine therapies: A clinical case report.
Dong P; Chen N; Li L; Huang R
Medicine (Baltimore); 2017 Oct; 96(41):e8215. PubMed ID: 29019888
[TBL] [Abstract][Full Text] [Related]
9. Ablation Rates and Long-Term Outcome Following Low-Dose Radioiodine for Differentiated Thyroid Cancer in the West of Scotland: A Retrospective Analysis.
Graham K; Tough F; Belikova H; Wotherspoon I; Colville D; Reed N
Endocr Pract; 2024 Apr; 30(4):327-332. PubMed ID: 38184240
[TBL] [Abstract][Full Text] [Related]
10. The value of the first postoperative diagnostic I-131 scan in patients with papillary thyroid carcinoma.
Ran B; Shang J; Chen Y; Zhou M; Li H; He W; Li Y; Cai Q; Guo B; Gong J; Xu H
J Cancer Res Clin Oncol; 2024 Feb; 150(2):80. PubMed ID: 38319395
[TBL] [Abstract][Full Text] [Related]
11. Basal or stimulated thyroglobulin in evaluating response to treatment in papillary thyroid carcinoma? A retrospective cohort study.
Barreto L; Ferreira DCG; Corrente JE; Soares CSP; Oliveira CC; Terra SA; Moriguchi SM; Koga KH; Tagliarini JV; da Silva Mazeto GMF
Hormones (Athens); 2024 Mar; 23(1):97-106. PubMed ID: 38015413
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine remnant ablation in low-risk differentiated thyroid cancer patients who had R0 dissection is an over treatment.
Bal C; Ballal S; Soundararajan R; Chopra S; Garg A
Cancer Med; 2015 Jul; 4(7):1031-8. PubMed ID: 25755077
[TBL] [Abstract][Full Text] [Related]
13. Shortened telomere length in peripheral blood leukocytes is associated with cumulative radioactive iodine doses in patients with differentiated thyroid carcinoma.
Choi H; Cho SW; Kim HH; Yi KH; Park DJ; Park YJ
Cancer; 2024 Jun; 130(12):2215-2223. PubMed ID: 38376914
[TBL] [Abstract][Full Text] [Related]
14. Papillary Thyroid Microcarcinoma: Differences between Lesions in Incidental and Nonincidental Settings-Considerations on These Clinical Entities and Personal Experience.
Lucandri G; Fiori G; Falbo F; Pende V; Farina M; Mazzocchi P; Santonati A; Bosco D; Spada A; Santoro E
Curr Oncol; 2024 Feb; 31(2):941-951. PubMed ID: 38392064
[TBL] [Abstract][Full Text] [Related]
15. The effect of COVID-19 pandemic restrictions on the management of differentiated thyroid cancer in Turkey: a single tertiary centre experience.
Calapkulu M; Sencar ME; Ozturk Unsal I; Sakiz D; Tekinyildiz M; Ozbek M; Cakal E
Eur Arch Otorhinolaryngol; 2024 May; 281(5):2587-2595. PubMed ID: 38347198
[TBL] [Abstract][Full Text] [Related]
16. Radioiodine Ablation following Thyroidectomy for Differentiated Thyroid Cancer: Literature Review of Utility, Dose, and Toxicity.
Andresen NS; Buatti JM; Tewfik HH; Pagedar NA; Anderson CM; Watkins JM
Eur Thyroid J; 2017 Jul; 6(4):187-196. PubMed ID: 28868259
[TBL] [Abstract][Full Text] [Related]
17. Summary and update on the management of differentiated thyroid cancer in 2023.
Raymond P; Klein M; Borson-Chazot F
Ann Endocrinol (Paris); 2024 Apr; 85(2):110-117. PubMed ID: 38316254
[TBL] [Abstract][Full Text] [Related]
18. Energy level and fatigue after surgery for thyroid cancer: A population-based study of patient-reported outcomes.
Hughes DT; Reyes-Gastelum D; Kovatch KJ; Hamilton AS; Ward KC; Haymart MR
Surgery; 2020 Jan; 167(1):102-109. PubMed ID: 31582311
[TBL] [Abstract][Full Text] [Related]
19. Radioactive Iodine Therapy in Differentiated Thyroid Cancer: An Update on Dose Recommendations and Risk of Secondary Primary Malignancies.
Nguyen NC; Anigati EM; Desai NB; Öz OK
Semin Nucl Med; 2024 May; ():. PubMed ID: 38772827
[TBL] [Abstract][Full Text] [Related]
20. Retrospective case-control study examining the relationship between recurrence-free survival and changes in pre- and post-radioiodine therapy serum thyroglobulin levels in patients with differentiated thyroid cancer.
Watanabe K; Igarashi T; Uchiyama M; Ishigaki T; Ojiri H
Jpn J Radiol; 2024 Apr; 42(4):391-397. PubMed ID: 38212512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
